Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease

References

• Carswell CI, Goa KL. Rabeprazole: an update of its use in acid related disorders. Drugs61(15), 2327–2356 (2001).
   PubMed Web of Science ®Google Scholar
• Ofman JJ, Dorn GH, Fennerty MB, Fass R. The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther.16(2), 261–273 (2002).
   PubMed Web of Science ®Google Scholar
• Remak E, Brown RE, Yuen C, Robinson A. Cost–effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK. Curr. Med. Res. Opin.21(10), 1505–1517 (2005).
   PubMed Web of Science ®Google Scholar
• Dubois D. Hughes DA, Bodger K, Bytzer P. Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease. Pharmacoeconomics23(10), 1031–1041 (2005).
   PubMedGoogle Scholar
• Kivioja A, Linnosmaa I, Vehvilainen A, Vohlonen I. Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions. Eur. J. Pharm. Sci.21(2–3), 171–178 (2004).
   PubMedGoogle Scholar
• Hall J, Dodd S, Durkin M, Sloan SA. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs. Manag. Care11(Suppl. 7), 14–18 (2002).
   PubMedGoogle Scholar
• Roche VF. The chemically elegant proton pump inhibitors. Am. J. Pharm. Educ.70(5), 101 (2006).
   PubMed Web of Science ®Google Scholar
• Kromer W, Kruger U, Huber R, Hartmann M, Steinijans VW. Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology56(2), 57–70 (1998).
   PubMed Web of Science ®Google Scholar
• Sachs G. Improving on PPI-based therapy of GORD. Eur. J. Gastroenterol. Hepatol.13(Suppl. 1), S35–S41 (2001).
   PubMedGoogle Scholar
• Tomiyama Y, Morii M, Takeguchi N. Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently. Biochem. Pharmacol.48(11), 2049–2055 (1994).
   PubMedGoogle Scholar
• Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J. Biol. Chem.272(36), 22438–22446 (1997).
   PubMed Web of Science ®Google Scholar
• Fock KM, Ang TL, Bee LC, Lee EJD. Proton pump inhibitors. Do differences in pharmacokinetics translate into differences in clinical outcomes? Clin. Pharmacokinet.47(1), 1–6 (2008).
   PubMed Web of Science ®Google Scholar
• Swan SK, Hoyumpa AM, Merrit GJ. Review article: the pharmacokinetics of rabeprazole in health and disease. Aliment. Pharmacol. Ther.13(3), 11–17 (1999).
   PubMed Web of Science ®Google Scholar
• Fuhr U, Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie57, 595–601 (2002).
   PubMed Web of Science ®Google Scholar
• James L, Walson P, Lomax K, Kao R, Varughese S, Reyes J; on behalf of the study 119 pediatric trial investigators. Pharmacokinetics and tolerability of rabeprazole sodium in subjects aged 12 to 16 years with gastroesophageal reflux disease: an open-label, single- and multiple-dose study. Clin. Ther.29, 2082–2092 (2007).
   PubMedGoogle Scholar
• Lim PW, Goh KL, Wong BC. CYP2C19 genotype and the PPIs – focus on rabeprazole. J. Gastroenterol. Hepatol.20, S22–S28 (2005).
   PubMedGoogle Scholar
• McColl KE, Kennerley P. Proton pump inhibitors – differences emerge in hepatic metabolism. Dig. Liver Dis.34(7), 461–467 (2002).
   PubMedGoogle Scholar
• Horn J. Review article: understanding the pharmacodynamic and pharmacokinetic differences between proton pump inhibitors – focus on pKa and metabolism. Aliment. Pharmacol. Ther.2, 340–350 (2006).
   Google Scholar
• Adachi K, Katsube T, Kawamura A et al.CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment. Pharmacol. Ther.13, 1259–1266 (2000).
   Google Scholar
• Ariizumi K, Ohara S, Koike T et al. Therapeutic effects of 10 mg once daily rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism. J. Gastroenterol. Hepatol.21(9), 1428–1434 (2006).
   PubMed Web of Science ®Google Scholar
• Ando T, Kato H, Sugimoto N et al. A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences. Dig. Dis. Sci.50(9), 1625–1631 (2005).
   PubMedGoogle Scholar
• Kawabata H, Habu Y, Tomioka H et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibotor, amoxicillin and clarithromycin. Aliment. Pharmacol. Ther.17(2), 259–264 (2003).
   PubMed Web of Science ®Google Scholar
• Kuwayama H, Asaka M, Sugiyama T et al. Rabeprazole-based eradication therapy for Helicobacter pylori: a large-scale study in Japan. Aliment. Pharmacol. Ther.25(9), 1105–1113 (2007).
   PubMed Web of Science ®Google Scholar
• Miura M, Inoue K, Kagaya H et al. Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. Biopharm. Drug Dispos.28(4), 167–175 (2007).
   PubMedGoogle Scholar
• Takahashi K, Yano I, Fukuhara Y et al. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient. Drug Metab. Pharmacokinet.22(6), 441–444 (2007).
   PubMedGoogle Scholar
• Robinson M, Barone J. Review article: comparative pharmacodynamic review of rabeprazole – focus on day 1 data. Aliment. Pharmacol. Ther.2, 315–326 (2006).
   Google Scholar
• Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment. Pharmacol. Ther.17, 1507–1514 (2003).
   PubMed Web of Science ®Google Scholar
• Luo JY, Niu CY, Wang XQ, Zhu YL, Gong J. Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude. World J. Gastroenterol.9(11), 2583–2586 (2003).
   PubMed Web of Science ®Google Scholar
• Norris V, Baisley K, Dunn K, Warrington S, Morocutti A. Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers. Aliment. Pharmacol. Ther.25, 501–510 (2007).
   PubMedGoogle Scholar
• Warrington S, Baisley K, Boyce M, Tejura B, Morocutti A, Miller N. Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24-h intragastric pH and serum gastrin in healthy subjects. Aliment. Pharmacol. Ther.16, 1301–1307 (2002).
   PubMed Web of Science ®Google Scholar
• Warrington S, Baisley K, Dunn K, Boyce M, Morocutti A. Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects. Eur. J. Clin. Pharmacol.62(9), 685–691 (2006).
   PubMedGoogle Scholar
• Warrington S, Baisley K, Lee D et al. Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. Aliment. Pharmacol. Ther.25, 511–517 (2007).
   PubMedGoogle Scholar
• Armstrong D, James C, Camacho F et al. Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. Aliment. Pharmacol. Ther.25, 185–196 (2006).
   PubMedGoogle Scholar
• Bruley Des Varannes S, Gharib H, Bicheler V et al. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects. Aliment. Pharmacol. Ther.20, 899–907 (2004).
   PubMedGoogle Scholar
• Shimatani T, Inoue M, Kuroiwa T et al. Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry. Dig. Dis. Sci.50(7), 1202–1206 (2005).
   PubMedGoogle Scholar
• Saitoh T, Fukushima Y, Otsuka H et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol. Ther.16, 1811–1817 (2002).
   PubMed Web of Science ®Google Scholar
• Shimatani T, Inoue M, Kuroiwa T et al. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Clin. Pharmacol. Ther.79, 144–152 (2006).
   PubMed Web of Science ®Google Scholar
• de Korwin JD, Ducrotté P, Vallot T. New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases? Presse Med.33(11), 746–754 (2004).
   PubMedGoogle Scholar
• Lee Y, Lin J, Wang H, Chiu H, Wu M. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. J. Gastroenterol. Hepatol.22, 1286–1292 (2007).
   PubMed Web of Science ®Google Scholar
• Sloan S. Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease. Am. J. Gastroenterol.98(Suppl. 3), S49–S55 (2003).
   Google Scholar
• Miner P Jr, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am. J. Gastroenterol.97(6), 1332–1339 (2002).
   PubMed Web of Science ®Google Scholar
• Fock KM, Teo EK, Ang TL, Chua TS, Ng TM, Tan YL. Rabeprazole vs esomeprazole in non-erosive gastro-esophageal reflux disease: a randomized, double-blind study in urban Asia. World J. Gastroenterol.11(20), 3091–3098 (2005).
   PubMed Web of Science ®Google Scholar
• Jacobson BC, Delemos B, Sun Y, Xiang J, Lococo J, Murphy A. Treatment outcomes with rabeprazole (RAB) 20 mg vs placebo (PBO) in overweight/obese patients with nonerosive reflux disease (NERD): analysis of two US multicenter trials. Acta of the 108th AGA scientific meeting, Abstract T1220. Gastroenterology132(4 Suppl. 2), A493 (2007).
   Google Scholar
• Thjodlejfsson B, Beker JA, Dekkers C. The European Rabeprazole Study Group. Rabeprazole vs omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double blind multicenter European trial. Dig. Dis. Sci.45(5), 845–853 (2000).
   PubMedGoogle Scholar
• Caos A, Moskovitz M, Dayal Y, Perdomo C, Niecestro R, Barth J. Rabeprazole Study Group. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Am. J. Gastroenterol.95(11), 3081–3088 (2000).
   PubMedGoogle Scholar
• Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ; The European Rabeprazole Study Group. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment. Pharmacol Ther.13(1), 49–57 (1999).
   PubMed Web of Science ®Google Scholar
• Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L; FAST Trial Investigators. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment. Pharmacol. Ther.16(3), 445–454 (2002).
   PubMed Web of Science ®Google Scholar
• Adachi K, Hashimoto T, Hamamoto N et al. Symptom relief in patients with reflux esophagitis: comparative study of omeprazole, lansoprazole, and rabeprazole. J. Gastroenterol. Hepatol.18(12), 1392–1398 (2003).
   PubMed Web of Science ®Google Scholar
• Pace F, Annese V, Prada A; Italian Rabeprazole Study Group. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux, followed by a maintenance open-label, low-dose therapy with rabeprazole. Dig. Liver Dis.37(10), 741–750 (2005).
   PubMedGoogle Scholar
• Bytzer P, Morocutti A, Kennerly P, Ravic M, Miller N; Rose Trial Investigators. Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. Scand. J. Gastroenterol.41(10), 1132–1140 (2006).
   PubMed Web of Science ®Google Scholar
• Pilotto A, Franceschi M, Leandro G et al. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World J. Gastroenterol.13(33), 4467–4472 (2007).
   PubMed Web of Science ®Google Scholar
• Miwa H, Sasaki M, Furuta T; ARS Research Group. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment. Pharmacol. Ther.26(1), 69–77 (2007).
   PubMed Web of Science ®Google Scholar
• Jacobson BC, Delemos B, Sun Y et al. PPI efficacy in overweight/obese patients with erosive GERD): rabeprazole (RAB) 20 mg vs Omeprazole (OME) 20 mg. Acta of the 72nd ACG scientific meeting, Abstract 89. Am. J. Gastroenterol.102(Suppl. 2), S150 (2007).
   Google Scholar
• Bytzer P, Blum A, De Herdt D, Dubois D, the Trial Investigators. Six-month trial of on demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease. Aliment. Pharmacol Ther.20, 181–188 (2004).
   PubMed Web of Science ®Google Scholar
• Pace F, Tonini M, Pallotta S, Molteni P, Porro GB. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken on demand. Aliment. Pharmacol. Ther.26, 195–204 (2007).
   PubMedGoogle Scholar
• Ponce J, Arguello L, Bastida G, Ponce M, Ortiz V, Garrigues V. On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. Dig. Dis. Sci.49(6), 931–936 (2004).
   PubMed Web of Science ®Google Scholar
• Bour B, Staub JL, Chousterman M et al. Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment. Pharmacol. Ther.21(7), 805–812 (2005).
   PubMed Web of Science ®Google Scholar
• Cotè GA, Ferriera MR, Rozenberg-Ben-Dror K, Howden CW. Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center. Aliment. Pharmacol. Ther.25, 709–714 (2007).
   PubMedGoogle Scholar
• Birbara C, Breiter J, Thjodleifsson B et al. European Rabeprazole Study Group. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment. Pharmacol. Ther.17(3), 343–351 (2003).
   PubMedGoogle Scholar
• Caos A, Breiter J, Perdomo C, Barth J. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs placebo: results of a 5-year study in the United States. Aliment. Pharmacol. Ther.22(3), 193–202 (2005).
   PubMedGoogle Scholar
• Rindi G, Fiocca R, Morocutti A, Jacobs A, Miller N, Thjodleifsson B; European Rabeprazole Study Group. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa. Eur. J. Gastroenterol. Hepatol.17(5), 559–566 (2005).
   PubMed Web of Science ®Google Scholar
• Morgan DG, O’Mahony MF, O’Mahony WF; RAB-GRD-3002 Study Group. Mainteinance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20 mg. Can. J. Gastroenterol.21(12), 820–826 (2007).
   PubMed Web of Science ®Google Scholar
• Barth J, Perdomo C, Sloan S. Rabeprazole maintains GERD healing in patients with Barrett’s esophagus (abstract and poster). Am. J. Gastroenterol.94, 2579 (1999).
   Google Scholar
• Wani S, Sampliner RE, Weston AP et al. Lack of predictors of normalization of oesophageal acid exposure in Barrett’s oesophagus. Aliment. Pharmacol. Ther.22(7), 627–633 (2005).
   PubMedGoogle Scholar
• Gerson LB, Shetler K, Triadafilopoulos G. Control of intra-oesophageal and intra-gastric pH with proton pump inhibitors in patients with Barrett’s oesophagus. Dig. Liver Dis.37(9), 651–658 (2005).
   PubMedGoogle Scholar
• Sarela AI, Hick DG, Verbeke CS, Casey JF, Guillou PJ, Clark GW. Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy. Arch. Surg.139(5), 547–551 (2004).
   PubMedGoogle Scholar
• Johnston MH, Eastone JA, Horwhat JD, Cartledge J, Mathews JS, Foggy JR. Cryoablation of Barrett’s esophagus: a pilot study. Gastrointest. Endosc.62(6), 842–848 (2005).
   PubMed Web of Science ®Google Scholar
• Oda K, Iwakiri R, Hara M et al. Dysphagia associated with gastroesophageal reflux disease is improved by proton pump inhibitor. Dig. Dis. Sci.50(10), 1921–1926 (2005).
   PubMedGoogle Scholar
• Dickman R, Emmons S, Cui H et al. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Aliment. Pharmacol. Ther.22(6), 547–555 (2005).
   PubMedGoogle Scholar
• Swiatkowski M, Budzynski J, Klopocka M et al. Suppression of gastric acid production may improve the course of angina pectoris and the results of treadmill stress test in patients with coronary artery disease. Med. Sci. Monit.10(9), CR524–CR529 (2004).
   PubMedGoogle Scholar
• Orr WC, Goodrich S, Robert J. The effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal reflux. Aliment. Pharmacol. Ther.21(2), 103–108 (2005).
   PubMed Web of Science ®Google Scholar
• Shaheen NJ, Madanick RD, Alattar M et al. Gastroesophageal reflux disease as an etiology of sleep disturbance in subjects with insomnia and minimal reflux symptoms: a pilot study of prevalence and response to therapy. Dig. Dis. Sci.23(4), 134–138 (2007).
   Google Scholar
• Tsugeno H, Mizuno M, Fujiki S et al. A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux. Scand. J. Gastroenterol.38(5), 456–461 (2003).
   PubMed Web of Science ®Google Scholar
• Peterson K, Fang J, Canale C, Ryujin D, Young D, Samuelson W. The role of gastroesophageal reflux (GER) in exercise triggered asthma. Acta of the 108th AGA scientific meeting, Abstract 913. Gastroenterology132(4 Suppl. 2), A140 (2007).
   Google Scholar
• Friedenberg FK, Simmons K, Palit A. Rabeprazole sodium 20 mg BID improves symptoms in patients with chronic persistent asthma. Acta of the 72nd ACG scientific meeting, Abstract 89. Am. J. Gastroenterol.102(Suppl. 2), S121–S122 (2007).
   Google Scholar
• Klopocka M, Sinkiewicz A, Budzynski J, Pulkowski G, Swiatkowski M. Improvement in clinical course and laryngeal appearance in selected patients with chronic laryngitis after eight weeks of therapy with rabeprazole. Med. Sci. Monit.10(10), PI115–PI118 (2004).
   PubMedGoogle Scholar
• Steward DL, Wilson KM, Kelly DH et al. Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial. Otolaryngol. Head Neck Surg.131(4), 342–350 (2004).
   PubMed Web of Science ®Google Scholar
• Suramethacul A, Isipradit P, Saengpanich S, Gonlachanvit S. Effect of high dose PPI (rabeprazole) on laryngopharyngeal reflux disease: a prospective, double blind, randomized controlled study. Acta of the 108th AGA scientific meeting, Abstract 915. Gastroenterology132(4 Suppl. 2), A140 (2007).
   Google Scholar
• Sone M, Yamamuro Y, Hayashi H, Yanagi E, Niwa Y, Nakashima T. Prediction of gastroesophageal reflux in otitis media with effusion in adults. Acta Oto-Laryngologica127, 470–473 (2007).
   PubMed Web of Science ®Google Scholar
• Sone M, Yamamuro Y, Hayashi H, Niwa Y, Nakashima T. Otitis media in adults as a symptom of gastroesophageal reflux. Otolaryngol. Head Neck Surg.136, 19–22 (2007).
   PubMed Web of Science ®Google Scholar
• Pawar S, Lim HJ, Gill M et al. Treatment of postnasal drip with proton pump inhibitors: a prospective, randomized, placebo controlled study. Am. J. Rhinol.21(6), 695–701 (2007).
   PubMedGoogle Scholar
• Morocutti A, Merrouche M, Bjaaland T, Humphries T, Mignon M. An open-label study of rabeprazole in patients with Zollinger–Ellison syndrome or idiopathic gastric acid hypersecretion. Aliment. Pharmacol. Ther.24(10), 1439–1444 (2006).
   PubMed Web of Science ®Google Scholar
• Giannini EG, Bilardi C, Dulbecco P et al. Can Helicobacter pylori eradication regimens be shortened in clinical practice? An open-label, randomized, pilot study of 4 and 7-day triple therapy with rabeprazole, high-dose levofloxacin, and tinidazole. J. Clin. Gastroenterol.40(6), 515–520 (2006).
   PubMedGoogle Scholar
• Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am. J. Gastroenterol.101(7), 1467–1475 (2006).
   PubMed Web of Science ®Google Scholar
• Shirai N, Sugimoto M, Kodaira C et al. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur. J. Clin. Pharmacol.63(8), 743–749 (2007).
   PubMed Web of Science ®Google Scholar
• Kawai T, Kawakami K, Mikinori K et al. Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan. Hepatogastroenterology54(74), 649–654 (2007).
   PubMedGoogle Scholar
• Choi HS, Park DI, Hwang SJ et al. Double-dose, new-generation proton pump inhibitors do not improve Helicobacter pylori eradication rate. Helicobacter12(6), 638–642 (2007).
   PubMed Web of Science ®Google Scholar
• Wu IC, Wu DC, Hsu PI et al. Rabeprazole- versus esomeprazole-based eradication regimens for H. pylori infection. Helicobacter12(6), 633–637 (2007).
   PubMed Web of Science ®Google Scholar
• Ji S, Kim HS, Kim JW et al. Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the healing rapidity of peptic ulcer diseases. J. Gastroenterol. Hepatol.21(9), 1381–1387 (2006).
   PubMedGoogle Scholar
• Ando T, Ishikawa T, Kokura S, Naito Y, Yoshida N, Yoshikawa T. Endoscopic analysis of gastric ulcer after one week’s treatment with omeprazole and rabeprazole in relation to CYP2C19 genotype. Dig. Dis. Sci.53(4), 933–937 (2007).
   PubMedGoogle Scholar
• Kim JI, Cheung DY, Cho SH et al. Oral proton pump inhibitors are as effective as endoscopic treatment for bleeding peptic ulcer: a prospective, randomized, controlled trial. Dig. Dis. Sci.52(12), 3371–3376 (2007).
   PubMedGoogle Scholar
• Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst. Rev.1, CD002094 (2006).
   Google Scholar
• Irani S, Krevsky B, Desipio J, Kim-Jaffe J, Maqbool S, Fisher RS. Rapid protection of the gastroduodenal mucosa against aspirin-induced damage by rabeprazole. Aliment. Pharmacol. Ther.27(6), 498–503 (2008).
   PubMed Web of Science ®Google Scholar
• Jaworski T, Sarosiek I, Sostarich S et al. Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: its potential clinical significance. Dig. Dis. Sci.50(2), 357–365 (2005).
   PubMedGoogle Scholar
• Salgueiro E, Rubio T, Hidalgo A, Manso G. Safety profile of proton pump inhibitors according to the spontaneous reports of suspected adverse reactions. Int. J. Clin. Pharmacol. Ther.44(11), 548–556 (2006).
   PubMed Web of Science ®Google Scholar
• Clark DW, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur. J. Clin. Pharmacol.62(6), 473–479 (2006).
   PubMed Web of Science ®Google Scholar
• Sanaka M, Anjiki H, Yamamoto T, Kuyama Y. Rabeprazole delays gastric emptying of a nutrient liquid. J. Gastroenterol. Hepatol.22(11), 1806–1809 (2007).
   PubMedGoogle Scholar
• Takahashi Y, Amano Y, Yuki T et al. Influence of acid suppressants on gastric emptying: cross-over analysis in healthy volunteers. J. Gastroenterol. Hepatol.21(11), 1664–1668 (2006).
   PubMed Web of Science ®Google Scholar
• Grudell AB, Camilleri M, Burton DD, Stephens DA. Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects: a pilot study. Aliment. Pharmacol. Ther.24(7), 1037–1043 (2006).
   PubMedGoogle Scholar
• Gralnek IM, Dulai GS, Fennerty BM, Spiegel BMR. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin. Gastroenterol. Hepatol.4, 1452–1458 (2006).
   PubMed Web of Science ®Google Scholar
• Edwards SJ, Lind T, Lundell L. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis – a comparison of esomeprazole with other PPIs. Aliment. Pharmacol. Ther.24, 743–750 (2006).
   PubMed Web of Science ®Google Scholar
• Hunt RH, Armstrong D, James C et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am. J. Gastroenterol.100(9), 1949–1956 (2005).
   PubMed Web of Science ®Google Scholar
• Pai V, Pai N. Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease. World J. Gastroenterol.13(30), 4100–4102 (2007).
   PubMedGoogle Scholar
• Pai V, Pai N. Recent developments: chiral switch in PPI therapy: S-pantoprazole. Br. Med. J.22, 112 (2006).
   Google Scholar